Literature DB >> 7821939

Primary pulmonary hypertension: natural history and prognostic factors.

D Rajasekhar1, K G Balakrishnan, C G Venkitachalam, J A Tharakan, T Titus, R Subramanian, V K Kumar, A Bhat, V R Pillai.   

Abstract

A retrospective cohort study was carried out in 61 patients (30 males, 31 females, age 24.6 +/- 11.8 years) with primary pulmonary hypertension diagnosed by strict clinical and hemodynamic criteria, to obtain an understanding of the natural history and prognostic markers. While 15 patients were alive, 46 patients (76%) had expired during the follow up period. Two, five and ten years survivals were 48%, 32% and 12% respectively. Median survival duration from time of diagnosis was 22 months. The survivors had significantly higher age of onset, cardiac index and significantly lower right atrial mean pressure, right ventricular end diastolic pressure, cardiothoracic ratio from chest rontgenogram and calculated pulmonary vascular resistance as compared to non survivors. While pulmonary artery systolic pressure was not significantly different, pulmonary artery diastolic and pulmonary artery mean pressures were significantly lower in survivors than in non-survivors. Lower New York Heart Association class, right atrial mean pressure < or = 7 mm Hg, right ventricular end diastolic pressure < or = 10 mmHg, cardiac index > 2.5 L/min/m2, pulmonary arterial oxygen saturation > 60%, were associated with significantly longer survival. The degree of pulmonary arterial hypertension had an indirect prognostic effect through the above parameters. Vasodilator therapy did not significantly alter the outcome of patients with primary pulmonary hypertension.

Entities:  

Mesh:

Year:  1994        PMID: 7821939

Source DB:  PubMed          Journal:  Indian Heart J        ISSN: 0019-4832


  3 in total

1.  Prevalence, incidence, and survival of pulmonary arterial hypertension: A systematic review for the global burden of disease 2020 study.

Authors:  Sophia Emmons-Bell; Catherine Johnson; Alexandra Boon-Dooley; Paul A Corris; Peter J Leary; Stuart Rich; Magdi Yacoub; Gregory A Roth
Journal:  Pulm Circ       Date:  2022-01-18       Impact factor: 2.886

2.  The impact of pulmonary arterial hypertension-targeted therapy on survival in Chinese patients with idiopathic pulmonary arterial hypertension.

Authors:  Wei-Jie Zeng; Yun-Juan Sun; Qing Gu; Chang-Ming Xiong; Jian-Jun Li; Jian-Guo He
Journal:  Pulm Circ       Date:  2012-07       Impact factor: 3.017

3.  Saudi guidelines on the diagnosis and treatment of pulmonary hypertension: 2014 updates.

Authors:  Majdy M Idrees; Sarfraz Saleemi; M Ali Azem; Saleh Aldammas; Manal Alhazmi; Javid Khan; Abdulgafour Gari; Maha Aldabbagh; Husam Sakkijha; Abdulla Aldalaan; Khalid Alnajashi; Waleed Alhabeeb; Imran Nizami; Amjad Kouatli; May Chehab; Omar Tamimi; Hanaa Banjar; Tarek Kashour; Antonio Lopes; Omar Minai; Paul Hassoun; Qadar Pasha; Eckhard Mayer; Ghazwan Butrous; Sastry Bhagavathula; Stefano Ghio; John Swiston; Adel Boueiz; Adriano Tonelli; Robert D Levy; Marius Hoeper; Rober D Levy
Journal:  Ann Thorac Med       Date:  2014-07       Impact factor: 2.219

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.